Biological Variation Database Structure and Criteria Used For Generation and Update
Biological Variation Database Structure and Criteria Used For Generation and Update
Carmen Perich, Joana Minchinela, Carmen Rics*, Pilar Fernndez-Calle, Virtudes Alvarez,
Mara Vicenta Domnech, Margarita Simn, Carmen Biosca, Beatriz Boned, Jos Vicente
Garca-Lario, Fernando Cava, Pilar Fernndez-Fernndez and Callum G. Fraser
Abstract
Background: Numerical data on the components of biological variation (BV) have many uses in laboratory
medicine, including in the setting of analytical quality
specifications, generation of reference change values and
assessment of the utility of conventional reference values.
Methods: Generation of a series of up-to-date comprehensive database of components of BV was initiated in 1997, integrating the more relevant information found in publications
concerning BV. A scoring system was designed to evaluate
the robustness of the data included. The database has been
updated every 2 years, made available on the Internet and
derived analytical quality specifications for imprecision, bias
and total allowable error included in the tabulation of data.
Results and conclusions: Our aim here is to document, in
detail, the methodology we used to evaluate the reliability
of the included data compiled from the published literature. To date, our approach has not been explicitly documented, although the principles have been presented at
many symposia, courses and conferences.
Keywords: biological variation; quality specifications; reference change values; reference intervals.
Abbreviations: BV, biological variation; CV, coefficient
of variation; CVI, within-subject coefficient of variation;
CVG, between-subject coefficient of variation; CVA, analytical coefficient of variation; CVI min and max, maximum
(CVI max) and minimum (CVI min) within-subject biological variation (CVI); EFLM, European Federation of Clinical
Chemistry and Laboratory Medicine; MM, mathematical
model score; PI, performance index score; RCV, reference
change value; SEQC, Spanish Society of Clinical Biochemistry and Molecular Pathology; STARD; standards for the
reporting of diagnostic accuracy studies.
Introduction
Data on the components of biological variation (BV),
namely, within-subject and between-subject BV, have
Our aim in this paper is to describe in detail the methodology used to document the criteria that have been
applied for inclusion or exclusion of the published data in
the database. To date, this has never been published in an
explicit and comprehensive way, although it has been presented at many symposia, courses and conferences over
the last 15 years.
In general, data with score 0 were not included in the final calculations, unless the second criterion, below, was fulfilled and no
more publications concerning the analyte were available.
b) Mathematical model (MM) used by the authors to calculate
CVI and CVG:
i) Score 4: ANOVA;
ii) Score 3: model described by Fraser and Harris [1, 9];
iii) Score 2: unclear model;
iv) Score 1: not described model.
Data with score 1 were not included in the final calculations.
3) Separation of data derived from studies on apparently healthy
adults: data derived from studies on subjects with documented
pathology are compiled in a different database.
4) Generation of estimates of CVI and CVG, using the median of all
data compiled.
Results
The database is maintained in a spreadsheet (MS Excel)
containing information on all the analytes studied. An
example of the database content is shown in Table 1. The
analyte selected is serum calcium, because the number of
available publications on BV is not so large as to make the
table difficult to read and understand. Once data generated
from subjects with documented pathology are separated to
a different file (data not shown in Table 1), the medians of
Table 1An example of the raw data tabulation for serum calcium derived from publications on biological variation.
CVI
CVG
CVA
PI
1.80
2.20
2.60
1.60
3.25
4.77
2.39
2.10
1.62
1.20
1.60
2.50
1.60
1.70
2.50
3.10
2.10
2.80
3.78
1.50
3.30
1.50
2.30
2.90
3.70
2.70
0.80
0.80
0.80
1.00
0.90
2.60
0.90
1.20
0.98
1.00
1.00
1.10
0.80
1.00
1.00
1.80
2.00
0.9
0.7
0.6
1.3
0.6
1.1
0.8
1.1
1.2
1.7
1.3
0.9
1.0
1.2
0.8
1.2
1.9
62
148
126
27
5
5
15
15
10
14
10
60
37
71
64
10
1105
Time
S/sub
Mean
1d
6m
6m
20 w
5d
5w
4w
40 w
8w
8w
8w
135 m
22 w
28 d
28 d
5d
8.5 w
4
6
6
10
5
5
4
10
8
8
8
2
22
7
7
5
9
2.5
2.4
2.4
2.36
2.5
2.5
2.4
2.41
2.33
2.29
2.32
2.41
2.4
2.4
Units
MM
Health
status
Year of
publication
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
mg/dL
mmol/L
3
3
3
4
4
4
3
3
3
3
3
4
3
4
4
3
2
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
1985
1985
1985
1989
1989
1989
1991
1987
1988
1987
1987
1990
1977
2013
2013
1986
1978
First author
Costongs [10]
Costongs [10]
Costongs [10]
Fraser [11]
Gallagher [12]
Gallagher [12]
Gonzalez-Revelderia [13]
Gowans [14]
Holzel [15]
Holzel [16]
Holzel [16]
Morris [17]
Pickup [18]
Pineda [19]
Pineda [19]
Rics [20]
Williams [21]
Cells without data indicate that the required information was not given in the original publication. Rows crossed out with horizontal bars,
indicate that the data therein were excluded from the final calculations, either because the PI is higher than 2 (Eckfeldt, Gallagher, Gowans,
Harris, Juan, Pineda, Van Steirteghem, Winkel), the CVA was not documented, or the MM score was 1. In consequence, the data in these rows
were not included in for the calculation of the median CVI and CVG. CVI, within-subject coefficient of variation; CVA, analytical coefficient of
variation; CVG, between-subject coefficient of variation; MM, mathematical model score; N, number of subjects studied; PI, performance
index score; S/sub, number of samples per subject; Time, duration of the study (h: hours, d: days, w: weeks, m: months, y: years).
Discussion
Table 2CVI estimates and range for analytes with more than nine
publications and the corresponding CVI range.
System Analyte
SSSSSSSSSSSSSBBSSSSSSSSSSSS-
Alanine
aminotransferase
Albumin
Alkaline phosphatase
Apolipoprotein A1
Aspartate
aminotransferase
Bilirubin, total
Calcium
Carcinoembryonic
Antigen
Chloride
Cholesterol
Creatinine
Glucose
HDL Cholesterol
Hematocrit
Hemoglobin
Iron
Lactate
dehydrogenase
Phosphate
Potassium
Protein, total
Sodium
Thyroxin
Triglyceride
Triiodothyronin
Urate
Urea
-Glutamyltransferase
CVI
range
10
19 17.3 5.358
25
21
11
13
42
32
15
22
3.1
6.5
6.5
12.8
1.511
2.713
3.610
8.224
11
24
10
16 21.8 1228
38 1.8 0.56.5
10 12.7 8.415
19
45
29
16
25
12
13
11
11
29
72
47
23
50
22
30
18
12
1.3
6.1
5.3
5.5
7.3
2.7
2.8
26.5
8.6
0.83.4
1.59.7
2.213
3.713
3.516
1.06.3
1.14.5
7.336
4.215
17
16
18
17
10
32
9
18
11
10
24
23
28
23
11
57
12
33
15
15
8.1
4.6
2.7
0.6
4.9
21.2
6.9
8.6
12.2
13.4
4.810
3.06.3
1.45.7
0.21.4
3.510
1239
5.710
2.517
4.816
3.935
it is apparent that it is from 1 to 2 for 55% of the analytes included in this group (Figure 1A), from 2 to 4 for
31% (Figure 1B) and from 4 to 7 for the remaining analytes (Figure 1C). This suggests that the distributions of
CVI values for the 86% of the analytes studied are generally quite compact and gives an idea of that differences
among publications are not important. There are four
exceptions, not shown in Figure 1 (urine proteins and
serum C-peptide, copper and ferritin, with ratios from 11
to 44) in which the estimated CVI could be considered as
less than robust.
Moreover, no significant relationships between the
CVI max/CVI min ratio and the number of publications or the
number of subject groups were evident.
For analytes with more than nine publications the
ratio CVI max/CVI min was from 1 to 7 indicating a compact
2.0
CVmax/CVmin
1.8
1.6
1.4
1.2
SHBG
p-Amy
Ig-l
Ca19,9
Endop
Crea
VLDLc
a2-Glo
DHEAs
Prol
HDL-2
LDH-5
IgM
Fibr
Lym-c
C3
Sod-bi
U-Ure
Aldo
FT3
F-Car
Cys
IgA
a1-Glo
Transf
Neu-c
CKMB-a
MCH
CRP
Zn
U-p-Amy
MCV
U-Pho
b-Glob
Pla-c
U-Alb
U-Ura
a1-Antrip
CK
TSH
Thyrog
Mon-c
MPV
Eos-c
U-Sod
Ery-Mg
b-Caro
F-VW
U-Mg
LDH-4
An T-III
Leu-c
Cy21,1
Ca++
a1-AcGlyc
Lyco
Testo
LDH-2
a-Toco
Cerul
Insu
NpBNP
Choli-a
IGF-1
1.0
4.0
CVmax/CVmin
3.6
3.2
2.8
2.4
2.0
CVmax/CVmin
LH
ApoB
APTT
DeoxPyr
Ca15.3
17OHP
Ery
Placrit
Homocy
Andr-dio
Lp-a
ACP
U-Cal
a-Amy
a2-Mac
Prothr-t
ALP-bone
TBG
cT-clTP
Bili-c
5Nuc
T-Carn
Cort
Estra
VitC
Fruc
Reti
ACP-tr
Lip
FSH
Baso-c
IgG
Oste
NAC
C4
Myog
NTIC
Choli-c
g-Glob
Ig-k
LDLC-m
AFP
1.6
8.0
7.0
6.0
5.0
4.0
PINP
FT4
MCHC
Hapt
TropI
PICP
s-Mg
PSA
TropT
U-Pot
Figure 1Ratio between maximum (CVI max) and minimum (CVI min) within-subject biological variation (CVI) documented for each analyte with
number of publications from 2 to 9.
(A) Analytes with CVmax/CVmin from 1 to 2. (B) Analytes with CVmax/CVmin from 2 to 4. (C) Analytes with CVmax/CVmin from 5 to 7.
12
Albumin
10
Calcium
Hematocrit
CVI
8
6
4
2
0
Different publications compiled
60
ALT
50
GGT
CVI
40
30
20
References
10
0
Different publications compiled
Figure 2Distribution of estimates of within-subject biological variation (CVI) for analytes with more than nine publications and with
apparently widely dispersed CVI.
whereas the test repertoires of many medical laboratories include approximately 1000 examinations; and
total allowable error derived from BV seems too
restrictive for some analytes as compared with current technological capability (e.g., serum sodium,
albumin and chloride and blood HbA1c) and too loose
for others with high BV (e.g., serum triglycerides and
urea).
Moreover, Carobene et al. [30] examined, in detail, all
accessible publications on the BV of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and
-glutamyltransferase (GGT). They found some discrepancies among the data in the publications; they suggested the need to develop a checklist such as that used
in the preparation of publications on diagnostic accuracy
studies, namely, the STARD guidelines [31], and assist in
the highest quality generation, compilation and publication of estimates of the components of BV.
We believe that this type of work would be improved
by preparing international guidelines on how to estimate
1. Fraser CG. Biological variation: from principles to practice. Washington DC: AACC Press, 2001.
2. Fraser CG. The application of theoretical goals based on biological variation data in proficiency testing. Arch Pathol Lab Med
1988;112:40415.
3. Fraser CG. Biological variation in clinical chemistry. An update:
collated data, 19881991. Arch Pathol Lab Med 1992;116:91623.
4. Sebastin-Gmbaro MA, Lirn-Hernndez FJ, Fuentes-Arderiu X.
Intra- and inter-individual biological variability data bank. Eur J
Clin Chem Clin Biochem 1997;35:84552.
5. Rics C, lvarez V, Cava F, Garca-Lario JV, Hernndez A, Jimnez
CV, etal. Current databases on biological variation: pros, cons
and progress. Scand J Clin Lab Invest 1999;59:491500.
6. Minchinela J, Rics C, Perich C, Fernndez-Calle P, Alvarez V,
Domnech MV, etal. Biological variation database and quality
specifications for imprecision, bias and total error (desirable and
minimum). The 2014 update. Available from: http://www.westgard.com/biodatabase-2014-update.htm. Accessed 7 July, 2014.
7. Minchinela J, Rics C, Perich C, Fernndez-Calle P, Alvarez V,
Domnech MV, etal. Base de datos de los componentes de Variacin Biolgica, con las especificaciones de la calidad analtica
(deseable, mnima y ptima). Actualizacin del ao 2014.
Available from: http:// www.seqc.es/es/Comisiones/18/9/102 /
Base_de_datos_de_Variacion_biologica_%7C_Comision_de_Calidad_Analitica_%7C_Comite_Cientifico/. Accessed 7 July, 2014.
8. Fraser CG, Browning MC. The index of fiduciality proposed
for use in evaluation and comparison of methods. Clin Chem
1988;34:13567.
9. Fraser CG, Harris EK. Generation and application of data on
biological variation in clinical chemistry. Crit Rev Clin Lab Sci
1989;27:40937.